Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease

Maurizio Battaglia Parodi, Marion R. Munk, Perluigi Iacono, Francesco Bandello

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularisation (CNV) associated with Stargardt disease. Methods Prospective, interventional, case series. All patients underwent intravitreal ranibizumab injections following a pro re nata regimen with monthly examination, over a 24-month follow-up. Results Three eyes were included in the study. Best corrected visual acuity changed from 0.47±0.06 (mean ±SD) at baseline to 0.90±0.17 LogMAR at the end of the 24-month follow-up. Overall, a mean number of 11 ranibizumab injections were administered in 24 months. Significant atrophic growth was detected in all cases, with the mean atrophy area increasing from 2.34±2.60 mm2 (mean±SD) at baseline to 4.23±3.31 mm2 at the end of the follow-up. Conclusions Ranibizumab treatment can stop the CNV progression, but cannot ensure a significant visual improvement. Macular atrophy tends to significantly enlarge under ranibizumab treatment over the follow-up.

Original languageEnglish
Pages (from-to)1268-1270
Number of pages3
JournalBritish Journal of Ophthalmology
Volume99
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Choroidal Neovascularization
Atrophy
Intravitreal Injections
Visual Acuity
Therapeutics
Ranibizumab
Stargardt disease 1
Injections
Growth

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease. / Parodi, Maurizio Battaglia; Munk, Marion R.; Iacono, Perluigi; Bandello, Francesco.

In: British Journal of Ophthalmology, Vol. 99, No. 9, 01.09.2015, p. 1268-1270.

Research output: Contribution to journalArticle

@article{46c90dc13ae14131b68d32fe824c2070,
title = "Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease",
abstract = "Introduction To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularisation (CNV) associated with Stargardt disease. Methods Prospective, interventional, case series. All patients underwent intravitreal ranibizumab injections following a pro re nata regimen with monthly examination, over a 24-month follow-up. Results Three eyes were included in the study. Best corrected visual acuity changed from 0.47±0.06 (mean ±SD) at baseline to 0.90±0.17 LogMAR at the end of the 24-month follow-up. Overall, a mean number of 11 ranibizumab injections were administered in 24 months. Significant atrophic growth was detected in all cases, with the mean atrophy area increasing from 2.34±2.60 mm2 (mean±SD) at baseline to 4.23±3.31 mm2 at the end of the follow-up. Conclusions Ranibizumab treatment can stop the CNV progression, but cannot ensure a significant visual improvement. Macular atrophy tends to significantly enlarge under ranibizumab treatment over the follow-up.",
author = "Parodi, {Maurizio Battaglia} and Munk, {Marion R.} and Perluigi Iacono and Francesco Bandello",
year = "2015",
month = "9",
day = "1",
doi = "10.1136/bjophthalmol-2014-305783",
language = "English",
volume = "99",
pages = "1268--1270",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Ranibizumab for subfoveal choroidal neovascularisation associated with Stargardt disease

AU - Parodi, Maurizio Battaglia

AU - Munk, Marion R.

AU - Iacono, Perluigi

AU - Bandello, Francesco

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Introduction To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularisation (CNV) associated with Stargardt disease. Methods Prospective, interventional, case series. All patients underwent intravitreal ranibizumab injections following a pro re nata regimen with monthly examination, over a 24-month follow-up. Results Three eyes were included in the study. Best corrected visual acuity changed from 0.47±0.06 (mean ±SD) at baseline to 0.90±0.17 LogMAR at the end of the 24-month follow-up. Overall, a mean number of 11 ranibizumab injections were administered in 24 months. Significant atrophic growth was detected in all cases, with the mean atrophy area increasing from 2.34±2.60 mm2 (mean±SD) at baseline to 4.23±3.31 mm2 at the end of the follow-up. Conclusions Ranibizumab treatment can stop the CNV progression, but cannot ensure a significant visual improvement. Macular atrophy tends to significantly enlarge under ranibizumab treatment over the follow-up.

AB - Introduction To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularisation (CNV) associated with Stargardt disease. Methods Prospective, interventional, case series. All patients underwent intravitreal ranibizumab injections following a pro re nata regimen with monthly examination, over a 24-month follow-up. Results Three eyes were included in the study. Best corrected visual acuity changed from 0.47±0.06 (mean ±SD) at baseline to 0.90±0.17 LogMAR at the end of the 24-month follow-up. Overall, a mean number of 11 ranibizumab injections were administered in 24 months. Significant atrophic growth was detected in all cases, with the mean atrophy area increasing from 2.34±2.60 mm2 (mean±SD) at baseline to 4.23±3.31 mm2 at the end of the follow-up. Conclusions Ranibizumab treatment can stop the CNV progression, but cannot ensure a significant visual improvement. Macular atrophy tends to significantly enlarge under ranibizumab treatment over the follow-up.

UR - http://www.scopus.com/inward/record.url?scp=84940600999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940600999&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2014-305783

DO - 10.1136/bjophthalmol-2014-305783

M3 - Article

C2 - 25740804

AN - SCOPUS:84940600999

VL - 99

SP - 1268

EP - 1270

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 9

ER -